Compare ORIO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | NNVC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Canada | United States |
| Employees | 178 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 22.2M |
| IPO Year | N/A | 2008 |
| Metric | ORIO | NNVC |
|---|---|---|
| Price | $1.11 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.7K | ★ 208.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $63.05 | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.85 |
| 52 Week High | $1.40 | $2.23 |
| Indicator | ORIO | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 51.06 |
| Support Level | $1.07 | $0.85 |
| Resistance Level | $1.25 | $1.07 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 40.00 | 68.69 |
Orion Digital Corp is a digital finance company operating across wealth, payments, and digital assets. Through its Investing wealth platform, Carta World-wide payments infrastructure, and long-duration Bitcoin treasury plan - combined with a disciplined, multi-engine compounding model. Orion Digital is focused on compounding value through execution, scale, and capital discipline.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.